Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2107-2119

  Fedyk, Eric R ^a   Wyant, Tim ^a   Yang, Li Li ^a   Csizmadia, Vilmos ^a   Burke, Kristine ^a   Yang, Hua ^b   Kadambi, Vivek J ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

4 7; LDP 02; MLN0002; MLN02; vedolizumab

Indexed keywords

ALPHA4BETA7 INTEGRIN; INTEGRIN; NATALIZUMAB; UNCLASSIFIED DRUG; VEDOLIZUMAB;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; ENTERITIS; FEMALE; HAPLORHINI; HISTOPATHOLOGY; INNATE IMMUNITY; LEUKOCYTE; LYMPHOCYTE; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASES; INTEGRINS; INTESTINAL MUCOSA; LEUKOCYTES; MACACA FASCICULARIS; MALE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84867576762     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22940     Document Type: Article

References (21)

1. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.
2. Agace WW,. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol. 2006; 6: 682-692.
3. von Adrian UH, Engelhardt B,. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003; 348: 68-72.
4. Tysabri (natalizumab) package insert 2010.
5. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 1912-1925.
6. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007; 132: 1672-1683.
7. Wehner NG, Gasper C, Shopp G, et al. Immunotoxicity profile of natalizumab. J Immunotoxicol. 2009; 6: 115-129.
8. Fuh F, David C, Hwang O, et al. Gut-homing CD4+ lymphocytes are specifically targeted in cynomolgus monkeys dosed with anti-beta7 antibodies. Gastroenterology. 2008; 134 (4, Suppl 1): A-99. Abstract 703.
9. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009; 330: 864-875.
10. Major EO,. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010; 61: 35-47.
11. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996; 111: 1373-1380.
12. Schippers A, Leuker C, Pabst O, et al. Mucosal addressin cell-adhesion molecule-1 controls plasma-cell migration and function in the small intestine of mice. Gastroenterology. 2009; 137: 924-933.
13. Gelzleichter TR, Hiraragi, H, Stefanich EG, et al.Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta 7 integrin antagonists. Patent application. US 2010/0255508 A1 07 Oct 2010.
14. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 24-32.
15. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005; 352: 2499-2507.
16. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008; 6: 1370-1377.
17. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008; 111: 3439-3441.
18. Zohren F, Toutzaris D, Klärner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008; 111: 3893-3895.
19. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348: 15-23.
20. Banerjee ER, Latchman YE, Jiang Y, et al. Distinct changes in adult lymphopoiesis in Rag2-/- mice fully reconstituted by alpha4-deficient adult bone marrow cells. Exp Hematol. 2008; 36: 1004-1013.
21. Brakebusch C, Fillatreau S, Potocnik AJ, et al. Beta1 integrin is not essential for hematopoiesis but is necessary for the T cell-dependent IgM antibody response. Immunity. 2002; 16: 465-477.